PIRFENIDONE

Search structure
Trade Names:
Synonyms:
Status: Approved (2011)
Entry Type: Small molecule
Molecule Category: UNKNOWN
ATC: L04AX05
UNII: D7NLD2JX7U

Structure
InChI Key ISWRGOKTTBVCFA-UHFFFAOYSA-N
Smile Cc1ccc(=O)n(-c2ccccc2)c1
InChI
InChI=1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3

Physicochemical Descriptors

Property Name Value
Molecular Formula C12H11NO
Molecular Weight 185.23
AlogP 2.15
Hydrogen Bond Acceptor 2.0
Hydrogen Bond Donor 0.0
Number of Rotational Bond 1.0
Polar Surface Area 22.0
Molecular species NEUTRAL
Aromatic Rings 2.0
Heavy Atoms 14.0

Pharmacology

Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Unclassified protein
- 1430 - - -

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Idiopathic Pulmonary Fibrosis 4 D054990 ClinicalTrials
Keloid 3 D007627 ClinicalTrials
Diabetic Foot 3 D017719 ClinicalTrials
Pneumonia 3 D011014 ClinicalTrials
Leiomyoma 2 D007889 ClinicalTrials
Glomerulosclerosis, Focal Segmental 2 D005923 ClinicalTrials
Nephrotic Syndrome 2 D009404 ClinicalTrials
Radiation Pneumonitis 2 D017564 ClinicalTrials
Proteinuria 2 D011507 ClinicalTrials
Liver Cirrhosis 2 D008103 ClinicalTrials
Pulmonary Fibrosis 2 D011658 ClinicalTrials
Burns 2 D002056 ClinicalTrials
Renal Insufficiency 2 D051437 ClinicalTrials
Renal Insufficiency, Chronic 2 D051436 ClinicalTrials
Renal Insufficiency 2 D051437 ClinicalTrials
Heart Failure 2 D006333 ClinicalTrials
Alveolitis, Extrinsic Allergic 2 D000542 ClinicalTrials
Severe Acute Respiratory Syndrome 2 D045169 ClinicalTrials
Pneumoconiosis 2 D011009 ClinicalTrials
Neurofibromatosis 1 2 D009456 ClinicalTrials
Scleroderma, Systemic 2 D012595 ClinicalTrials
Lung Diseases, Interstitial 2 D017563 ClinicalTrials
Bronchiolitis Obliterans 2 D001989 ClinicalTrials
Cardiomyopathy, Hypertrophic 2 D002312 ClinicalTrials
Multiple Sclerosis 1 D009103 ClinicalTrials

Related Entries

MCS

Scaffolds

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Gastrointestinal disorders
16.52
General disorders and administration site conditions
16.05
Respiratory, thoracic and mediastinal disorders
11.64
Nervous system disorders
8.72
Cardiac disorders
6.47
Skin and subcutaneous tissue disorders
6.42
Investigations
5.89
Psychiatric disorders
5.17
Vascular disorders
4.4
Infections and infestations
4.02
Metabolism and nutrition disorders
4.0
Musculoskeletal and connective tissue disorders
2.9
Injury, poisoning and procedural complications
2.38

Cross References

Resources Reference
CAS NUMBER 53179-13-8
ChEBI 32016
ChEMBL CHEMBL1256391
DrugBank DB04951
DrugCentral 4224
EPA CompTox DTXSID4045183
FDA SRS D7NLD2JX7U
Guide to Pharmacology 7532
PubChem 40632
SureChEMBL SCHEMBL4708
ZINC ZINC000000001958
CONTENTS